A citation-based method for searching scientific literature

G S Falchook, J C Trent, M C Heinrich, C Beadling, J Patterson, C C Bastida, S C Blackman, R Kurzrock. Oncotarget 2013
Times Cited: 93







List of co-cited articles
830 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Narasimhan P Agaram, Grace C Wong, Tianhua Guo, Robert G Maki, Samuel Singer, Ronald P Dematteo, Peter Besmer, Cristina R Antonescu. Genes Chromosomes Cancer 2008
242
41

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
S Hirota, K Isozaki, Y Moriyama, K Hashimoto, T Nishida, S Ishiguro, K Kawano, M Hanada, A Kurata, M Takeda,[...]. Science 1998
38

BRAF mutation status in gastrointestinal stromal tumors.
Isabelle Hostein, Nicolas Faur, Charlotte Primois, Frédérique Boury, Jérome Denard, Jean-François Emile, Pierre-Paul Bringuier, Jean-Yves Scoazec, Jean-Michel Coindre. Am J Clin Pathol 2010
135
32

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
Claudia Miranda, Martina Nucifora, Francesca Molinari, Elena Conca, Maria Chiara Anania, Andrea Bordoni, Piercarlo Saletti, Luca Mazzucchelli, Silvana Pilotti, Marco A Pierotti,[...]. Clin Cancer Res 2012
121
31

PDGFRA activating mutations in gastrointestinal stromal tumors.
Michael C Heinrich, Christopher L Corless, Anette Duensing, Laura McGreevey, Chang-Jie Chen, Nora Joseph, Samuel Singer, Diana J Griffith, Andrea Haley, Ajia Town,[...]. Science 2003
31

V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
A Agaimy, L M Terracciano, S Dirnhofer, L Tornillo, A Foerster, A Hartmann, M P Bihl. J Clin Pathol 2009
134
29

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
George D Demetri, Peter Reichardt, Yoon-Koo Kang, Jean-Yves Blay, Piotr Rutkowski, Hans Gelderblom, Peter Hohenberger, Michael Leahy, Margaret von Mehren, Heikki Joensuu,[...]. Lancet 2013
748
29

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Michael C Heinrich, Christopher L Corless, George D Demetri, Charles D Blanke, Margaret von Mehren, Heikki Joensuu, Laura S McGreevey, Chang-Jie Chen, Annick D Van den Abbeele, Brian J Druker,[...]. J Clin Oncol 2003
27

Gastrointestinal stromal tumors: pathology and prognosis at different sites.
Markku Miettinen, Jerzy Lasota. Semin Diagn Pathol 2006
27

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
George D Demetri, Allan T van Oosterom, Christopher R Garrett, Martin E Blackstein, Manisha H Shah, Jaap Verweij, Grant McArthur, Ian R Judson, Michael C Heinrich, Jeffrey A Morgan,[...]. Lancet 2006
25

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.
Katherine A Janeway, Su Young Kim, Maya Lodish, Vânia Nosé, Pierre Rustin, José Gaal, Patricia L M Dahia, Bernadette Liegl, Evan R Ball, Margarita Raygada,[...]. Proc Natl Acad Sci U S A 2011
388
23

Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).
Marc Daniels, Irene Lurkin, Roland Pauli, Erhard Erbstösser, Uwe Hildebrandt, Karsten Hellwig, Uwe Zschille, Petra Lüders, Gabriele Krüger, Jürgen Knolle,[...]. Cancer Lett 2011
101
22

Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age.
Markku Miettinen, Zeng-Feng Wang, Maarit Sarlomo-Rikala, Czeslaw Osuch, Piotr Rutkowski, Jerzy Lasota. Am J Surg Pathol 2011
203
21

Gastrointestinal stromal tumours: origin and molecular oncology.
Christopher L Corless, Christine M Barnett, Michael C Heinrich. Nat Rev Cancer 2011
479
21

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Michael C Heinrich, Kouros Owzar, Christopher L Corless, Donna Hollis, Ernest C Borden, Christopher D M Fletcher, Christopher W Ryan, Margaret von Mehren, Charles D Blanke, Cathryn Rankin,[...]. J Clin Oncol 2008
404
20

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Charles D Blanke, Annick D Van den Abbeele, Burton Eisenberg, Peter J Roberts, Michael C Heinrich, David A Tuveson, Samuel Singer, Milos Janicek,[...]. N Engl J Med 2002
20

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Michael C Heinrich, Robert G Maki, Christopher L Corless, Cristina R Antonescu, Amy Harlow, Diana Griffith, Ajia Town, Arin McKinley, Wen-Bin Ou, Jonathan A Fletcher,[...]. J Clin Oncol 2008
491
20

Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Sosipatros A Boikos, Alberto S Pappo, J Keith Killian, Michael P LaQuaglia, Chris B Weldon, Suzanne George, Jonathan C Trent, Margaret von Mehren, Jennifer A Wright, Josh D Schiffman,[...]. JAMA Oncol 2016
152
19

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
18

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
Michael C Heinrich, Diana Griffith, Arin McKinley, Janice Patterson, Ajia Presnell, Abhijit Ramachandran, Maria Debiec-Rychter. Clin Cancer Res 2012
137
18

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
Eileen Shi, Juliann Chmielecki, Chih-Min Tang, Kai Wang, Michael C Heinrich, Guhyun Kang, Christopher L Corless, David Hong, Katherine E Fero, James D Murphy,[...]. J Transl Med 2016
100
18


KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Maria Debiec-Rychter, Raf Sciot, Axel Le Cesne, Marcus Schlemmer, Peter Hohenberger, Allan T van Oosterom, Jean-Yves Blay, Serge Leyvraz, Michel Stul, Paolo G Casali,[...]. Eur J Cancer 2006
608
17

Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
B Liegl, I Kepten, C Le, M Zhu, G D Demetri, M C Heinrich, C D M Fletcher, C L Corless, J A Fletcher. J Pathol 2008
283
16

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Cristina R Antonescu, Ronald P DeMatteo, Kristen N Ganjoo, Robert G Maki, Peter W T Pisters, Chandrajit P Raut, Richard F Riedel, Scott Schuetze,[...]. J Natl Compr Canc Netw 2010
704
16

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
Christopher L Corless, Arin Schroeder, Diana Griffith, Ajia Town, Laura McGreevey, Patina Harrell, Sharon Shiraga, Troy Bainbridge, Jason Morich, Michael C Heinrich. J Clin Oncol 2005
548
16


Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
Michael C Heinrich, Christopher L Corless, Charles D Blanke, George D Demetri, Heikki Joensuu, Peter J Roberts, Burton L Eisenberg, Margaret von Mehren, Christopher D M Fletcher, Katrin Sandau,[...]. J Clin Oncol 2006
556
15

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Paul T C Wan, Mathew J Garnett, S Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, C Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford,[...]. Cell 2004
15

Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.
Barbara Pasini, Sarah R McWhinney, Thalia Bei, Ludmila Matyakhina, Sotirios Stergiopoulos, Michael Muchow, Sosipatros A Boikos, Barbara Ferrando, Karel Pacak, Guillaume Assie,[...]. Eur J Hum Genet 2008
299
13

Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor.
J Keith Killian, Su Young Kim, Markku Miettinen, Carly Smith, Maria Merino, Maria Tsokos, Martha Quezado, William I Smith, Mona S Jahromi, Paraskevi Xekouki,[...]. Cancer Discov 2013
204
13

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Jaap Verweij, Paolo G Casali, John Zalcberg, Axel LeCesne, Peter Reichardt, Jean-Yves Blay, Rolf Issels, Allan van Oosterom, Pancras C W Hogendoorn, Martine Van Glabbeke,[...]. Lancet 2004
13

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran,[...]. JAMA 2012
573
13

Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad.
Florian Haller, Evgeny A Moskalev, Fabio R Faucz, Sarah Barthelmeß, Stefan Wiemann, Matthias Bieg, Guillaume Assie, Jerome Bertherat, Inga-Marie Schaefer, Claudia Otto,[...]. Endocr Relat Cancer 2014
110
13

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.
Heikki Joensuu, Aki Vehtari, Jaakko Riihimäki, Toshirou Nishida, Sonja E Steigen, Peter Brabec, Lukas Plank, Bengt Nilsson, Claudia Cirilli, Chiara Braconi,[...]. Lancet Oncol 2012
494
13

Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation.
Markku Miettinen, Jonathan Keith Killian, Zeng-Feng Wang, Jerzy Lasota, Christopher Lau, Laura Jones, Robert Walker, Marbin Pineda, Yuelin Jack Zhu, Su Y Kim,[...]. Am J Surg Pathol 2013
113
12

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Ping Chi, Yu Chen, Lei Zhang, Xingyi Guo, John Wongvipat, Tambudzai Shamu, Jonathan A Fletcher, Scott Dewell, Robert G Maki, Deyou Zheng,[...]. Nature 2010
205
12

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.
Bengt Nilsson, Per Bümming, Jeanne M Meis-Kindblom, Anders Odén, Aydin Dortok, Bengt Gustavsson, Katarzyna Sablinska, Lars-Gunnar Kindblom. Cancer 2005
834
12

Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
Chiara Mussi, Hans-Ulrich Schildhaus, Alessandro Gronchi, Eva Wardelmann, Peter Hohenberger. Clin Cancer Res 2008
98
12

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Charles D Blanke, Cathryn Rankin, George D Demetri, Christopher W Ryan, Margaret von Mehren, Robert S Benjamin, A Kevin Raymond, Vivien H C Bramwell, Laurence H Baker, Robert G Maki,[...]. J Clin Oncol 2008
693
12

Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
Sebastian Huss, Helen Pasternack, Michaela Angelika Ihle, Sabine Merkelbach-Bruse, Birthe Heitkötter, Wolfgang Hartmann, Marcel Trautmann, Heidrun Gevensleben, Reinhard Büttner, Hans-Ulrich Schildhaus,[...]. Hum Pathol 2017
22
54

Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.
Monica Brenca, Sabrina Rossi, Maurizio Polano, Daniela Gasparotto, Lucia Zanatta, Dominga Racanelli, Laura Valori, Stefano Lamon, Angelo Paolo Dei Tos, Roberta Maestro. J Pathol 2016
99
12

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Olivier Mir, Claire Cropet, Maud Toulmonde, Axel Le Cesne, Mathieu Molimard, Emmanuelle Bompas, Philippe Cassier, Isabelle Ray-Coquard, Maria Rios, Antoine Adenis,[...]. Lancet Oncol 2016
60
20

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
Chi Tarn, Lori Rink, Erin Merkel, Douglas Flieder, Harsh Pathak, Daphne Koumbi, Joseph R Testa, Burton Eisenberg, Margaret von Mehren, Andrew K Godwin. Proc Natl Acad Sci U S A 2008
186
11


Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Ronald P Dematteo, Karla V Ballman, Cristina R Antonescu, Robert G Maki, Peter W T Pisters, George D Demetri, Martin E Blackstein, Charles D Blanke, Margaret von Mehren, Murray F Brennan,[...]. Lancet 2009
865
11

Diagnosis of gastrointestinal stromal tumors: A consensus approach.
Christopher D M Fletcher, Jules J Berman, Christopher Corless, Fred Gorstein, Jerzy Lasota, B Jack Longley, Markku Miettinen, Timothy J O'Leary, Helen Remotti, Brian P Rubin,[...]. Hum Pathol 2002
11

Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.
Leili Ran, Inna Sirota, Zhen Cao, Devan Murphy, Yuedan Chen, Shipra Shukla, Yuanyuan Xie, Michael C Kaufmann, Dong Gao, Sinan Zhu,[...]. Cancer Discov 2015
77
14

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Charles D Blanke, George D Demetri, Margaret von Mehren, Michael C Heinrich, Burton Eisenberg, Jonathan A Fletcher, Christopher L Corless, Christopher D M Fletcher, Peter J Roberts, Daniela Heinz,[...]. J Clin Oncol 2008
672
11

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
967
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.